Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases

The biology of VEGF and its receptors

Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

Met, metastasis, motility and more

Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

Schmidt, L. S., Duh, F.-M. C., Chen, F., Kishida, T., Glenn, G. M., Choyke, P. L., Scherer, S. W., Zhuang, Z., Lubensky, I. A., Dean, M. C., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,517

Active and Inactive Protein Kinases: Structural Basis for Regulation

Johnson, L. N., Noble, M. E. M., & Owen, D. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81092-2 · Cited by 1,396

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. K., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,361

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Bergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192

Drug development of MET inhibitors: targeting oncogene addiction and expedience

Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 832

Development of efficient docking strategies and structure-activity relationship study of the c-Met type II inhibitors

Li, M., Wu, G., Kaas, Q., Jiang, T., & Yu, R. (2017) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2017.04.004 · Cited by 20

New Insights into the Management of Renal Cell Cancer

Pécuchet, N., Fournier, L. S., & Oudard, S. M. (2012) · Oncology · doi:10.1159/000342962 · Cited by 19

Synthesis and Antimicrobial Activity of 1,3,4‐Oxadiazole‐2(3H)‐thione and Azidomethanone Derivatives Based on Quinoline‐4‐carbohydrazide Derivatives

Mohamed, M. I., Kandile, N. G., & Zaky, H. T. (2015) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.2529 · Cited by 19

Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets

Sumi, N. J., Ctortecka, C., Hu, Q., Bryant, A. T., Fang, B., Rix, L. L. R., Ayaz, M., Kinose, F., Welsh, E. A., Eschrich, S. A., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.06.003 · Cited by 21

MET inhibition in lung cancer.

Menis, J., Levra, M. G., & Novello, S. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.12.04 · Cited by 17

Tivantinib: A New Promising Mesenchymal–Epithelial Transition Factor Inhibitor in the Treatment of Hepatocellular Carcinoma

Rimassa, L., Personeni, N., Simonelli, M., & Santoro, A. (2013) · Future Oncology · doi:10.2217/fon.12.188 · Cited by 18

Bioorthogonal Small Molecule Imaging Agents Allow Single-Cell Imaging of MET

Kim, E., Yang, K. S., & Weissleder, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081275 · Cited by 18

Targeting the MET Pathway in Gastric and Oesophageal Cancers: Refining the Optimal Approach

Lee, J., Tran, P. N., & Klempner, S. J. (2016) · Clinical Oncology · doi:10.1016/j.clon.2016.01.009 · Cited by 17

An Introduction and Overview of RON Receptor Tyrosine Kinase Signaling

Hunt, B. G., Fox, L. H., Davis, J. C., Jones, A. D., Lu, Z., & Waltz, S. E. (2023) · Genes · doi:10.3390/genes14020517 · Cited by 17

Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma

Flaherty, K. T., & Puzanov, I. J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.005 · Cited by 16

A Comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors

Naing, A., Kurzrock, R., Adams, L. M., Kleha, J. F., Laubscher, K. H., Bonate, P. L., Weller, S., Fitzgerald, C., Xu, Y., & LoRusso, P. M. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9536-x · Cited by 17

Quantitative Chemical Proteomics Identifies Novel Targets of the Anti-cancer Multi-kinase Inhibitor E-3810

Colzani, M., Noberini, R., Romanenghi, M., Colella, G., Pasi, M., Fancelli, D., Varasi, M., Minucci, S., & Bonaldi, T. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.034173 · Cited by 17

Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors

Singh, R. P., Patel, B. R., Kallender, H., Ottesen, L. H., Adams, L. M., & Cox, D. S. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.546 · Cited by 17

The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences

Fogli, S., Tabbò, F., Capuano, A., Re, M. D., Passiglia, F., Cucchiara, F., Scavone, C., Gori, V., Novello, S., Schmidinger, M., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103602 · Cited by 17

Anti‐angiogenic and anti‐tumor effects of TAK ‐593, a potent and selective inhibitor of vascular endothelial growth factor and platelet‐derived growth factor receptor tyrosine kinase

Awazu, Y., Mizutani, A., Nagase, Y., Tsuchiya, S., Nakamura, K., Kakoi, Y., Kitahara, O., Takeuchi, T., Yamasaki, S., Miyamoto, N., et al. (2013) · Cancer Science · doi:10.1111/cas.12101 · Cited by 17

Synthesis and Antitumor Activity of Novel 4‐(2‐ F luorophenoxy)quinoline Derivatives Bearing the 4‐ O xo‐1,4‐dihydroquinoline‐3‐carboxamide Moiety

Li, S., Jiang, R., Qin, M., Liu, H., Zhang, G., & Gong, P. (2013) · Archiv der Pharmazie · doi:10.1002/ardp.201300029 · Cited by 17

Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold

Jiang, X., Liu, H., Song, Z., Xia, P., Ji, Y., Yao, Q., Geng, M., Ai, J., & Zhang, A. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.002 · Cited by 16

Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors

Wulkersdorfer, B., Zeitlinger, M. A., & Schmid, M. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0302-2 · Cited by 16

Non-clear cell advanced kidney cancer

Sánchez, P., Calvo, E., & Durán, I. (2010) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000390767.85658.83 · Cited by 17

Monitoring activities of receptor tyrosine kinases using a universal adapter in genetically encoded split TEV assays

Wintgens, J. P., Wichert, S. P., Popović, L., Rossner, M. J., & Wehr, M. C. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-03003-2 · Cited by 16

Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors

Szokol, B., Gyulavári, P., Ibolya, K., Baska, F., Szántai-Kis, C., Greff, Z., Őrfi, Z., Peták, I., Pénzes, K., Torka, R., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4003309 · Cited by 15

AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies

Vandewalle, N., Beule, N. D., Becker, A. D., Bruyne, E. D., Menu, E., Vanderkerken, K., Breckpot, K., Devoogdt, N., & Veirman, K. D. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00566-8 · Cited by 14

Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?

Bruce, D. J., & Tan, P. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.611801 · Cited by 14

Novel 4-phenoxypyridine derivatives bearing imidazole-4-carboxamide and 1,2,4-triazole-3-carboxamide moieties: Design, synthesis and biological evaluation as potent antitumor agents

Liu, J., Liu, F., Li, Z., Li, C., Wu, S., Shen, J., Wang, H., Du, S., Hao, W., Hou, Y., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105629 · Cited by 14

Silencing ofEag1Gene Inhibits Osteosarcoma Proliferation and Migration by Targeting STAT3-VEGF Pathway

Wu, X., Chen, Z., Zeng, W., Zhong, Y., Liu, Q., & Wu, J. (2015) · BioMed Research International · doi:10.1155/2015/617316 · Cited by 15

Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer

Kogata, Y., Tanaka, T., Ono, Y. J., Hayashi, M., Terai, Y., & Ohmichi, M. (2018) · Oncotarget · doi:10.18632/oncotarget.25232 · Cited by 14

Structure activity relationships of chrysoeriol and analogs as dual c‑Met and VEGFR2 tyrosine kinase inhibitors

Lai, S., Chen, J., Huang, H., Zhang, X., Jiang, H., Li, W., Wang, P., Wang, J., & Liu, F. (2018) · Oncology Reports · doi:10.3892/or.2018.6542 · Cited by 14

Molecular modelling study on pyrrolo[2,3-b]pyridine derivatives as c-Met kinase inhibitors: a combined approach using molecular docking, 3D-QSAR modelling and molecular dynamics simulation

Shirvani, P., & Fassihi, A. (2020) · Molecular Simulation · doi:10.1080/08927022.2020.1810853 · Cited by 15

Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1 H -pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors

Zhang, L., Zhang, B., Zhao, J., Zhi, Y., Wang, L., Lu, T., & Chen, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.057 · Cited by 13

Novel therapeutic targets and predictive markers for hepatocellular carcinoma

Chan, S. L., Chan, A. W. H., & Yeo, W. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1031109 · Cited by 12

Discovery of a potent and selective Axl inhibitor in preclinical model

Inoue, S., Yamane, Y., Tsukamoto, S., Azuma, H., Nagao, S., Murai, N., Nishibata, K., Fukushima, S., Ichikawa, K., Nakagawa, T., et al. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116137 · Cited by 12

Design, synthesis and anticancer evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 1,8-naphthyridine-3-carboxamide moiety as novel multi-target TKIs

Chen, P., Zhao, Y. H., Zhang, J., Duan, Y., Dai, J., He, J., Wang, X., Chen, X., Chen, P., Zhao, W., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105672 · Cited by 12

Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib

Wang, P., Zhang, Y., Xiang, R., Yang, J., Xu, Y., Deng, T., Zhou, W., Wang, C., Xiao, X., & Wang, S. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1534 · Cited by 12

Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors

Srivastava, A. K., Hollingshead, M. G., Govindharajulu, J. P., Covey, J. M., Liston, D. R., Simpson, M. A., Peggins, J. O., Bottaro, D. P., Wright, J. J., Kinders, R. J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0552 · Cited by 12

Induction of protective and therapeutic antitumor immunity by a DNA vaccine with C3d as a molecular adjuvant

Xu, G., Zhang, K., Guo, B., Zhao, T., Yang, F., Jiang, M., Wang, Q., Shang, Y.-H., & Wu, Y. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.057 · Cited by 12

The Role of HGF/c-Met Pathway Signaling in Human Medulloblastoma

Faria, C. C., Smith, C. A., & Rutk, J. (2011) · InTech eBooks · doi:10.5772/23296 · Cited by 14

Therapeutic implications of signaling pathways and tumor microenvironment interactions in esophageal cancer

Khan, I. R., Sadida, H. Q., Hashem, S., Singh, M. K., Macha, M. A., Akil, A. S. A.-S., Khurshid, I., & Bhat, A. A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116873 · Cited by 12

The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells

Kucińska, M., Pospieszna, J., Tang, J. P., Lisiak, N., Totoń, E., Rubiś, B., & Murias, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116892 · Cited by 11

Novel Approaches Targeting the Vascular Endothelial Growth Factor Axis in Renal Cell Carcinoma

Voss, M. H., Hsieh, J. J.-D., & Motzer, R. J. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e31829d5cff · Cited by 11

MET targeted therapy for lung cancer: clinical development and future directions

Ma, P., & Feng, Y. (2012) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s23423 · Cited by 11

Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout

Favoni, R. E., & Alama, A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.011 · Cited by 11

Dual leucine zipper kinase (MAP3K12) modulators: a patent review (2010–2015)

Oetjen, E., & Lemcke, T. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1170810 · Cited by 11

Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015

Pollmann, S. E., Calvert, V. S., Rao, S., Boca, S. M., Madhavan, S., Horak, I. D., Kjær, A., Petricoin, E. F., Kragh, M., & Poulsen, T. T. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0787 · Cited by 11

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC

Kim, N. A., Hong, S., Kim, K. H., Choi, D. H., Kim, J. S., Park, K. E., Choi, J. Y., Shin, Y. K., & Jeong, S. H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020121 · Cited by 11

Metabolic Regulation of T Cell Immunity

Vignali, P., Barbi, J. J., & Pan, F. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-94-024-1170-6_2 · Cited by 10

Novel biomolecules in targeted cancer therapy: a new approach towards precision medicine

Kannampuzha, S., Murali, R., Gopalakrishnan, A. V., Mukherjee, A. G., Wanjari, U. R., Namachivayam, A., George, A., Dey, A., & Vellingiri, B. (2023) · Medical Oncology · doi:10.1007/s12032-023-02168-6 · Cited by 11

Uses of Anthranilic Acid for the Synthesis of Dihydroquinazolin Derivatives with Antitumor, Antiproliferative and Pim-1 kinase Activities

Mohareb, R. M., & Halim, P. A. (2018) · Acta chimica slovenica · doi:10.17344/acsi.2017.4146 · Cited by 10

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

Yao, H., Tong, X., & Wang, M. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211006957 · Cited by 10

Role of Met Axis in Head and Neck Cancer

Xu, Y., & Fisher, G. J. (2013) · Cancers · doi:10.3390/cancers5041601 · Cited by 10

Inflammation-Induced Metastatic Colonization of the Lung Is Facilitated by Hepatocyte Growth Factor-Secreting Monocyte-Derived Macrophages

Arif, A. A., Huang, Y.-H., Freeman, S. A., Atif, J., Dean, P., Lai, J. C. Y., Blanchet, M., Wiegand, K. C., McNagny, K. M., Underhill, T. M., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0009 · Cited by 9

Synthesis and biological evaluation of novel (E)-N'-benzylidene hydrazides as novel c-Met inhibitors through fragment based virtual screening

Liang, J., Li, S., Wang, S., Li, W., & Meng, F. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1702655 · Cited by 10

trans-Fluorine Effect in Cyclopropane: Diastereoselective Synthesis of Fluorocyclopropyl Cabozantinib Analogs

Veliks, J., Ozola, M., Kinēns, A., Bobrovs, R., Priede, M., & Kuka, J. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00220 · Cited by 9

Combination of multifunctional ursolic acid with kinase inhibitors for anti-cancer drug carrier vesicles

Lörincz, A., Mihály, J., Wacha, A., Németh, C., Besztercei, B., Gyulavári, P., Varga, Z., Peták, I., & Bóta, A. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112481 · Cited by 9

Emerging drugs for renal cell carcinoma

Varella, L., & Rini, B. I. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.486788 · Cited by 9

Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding

Grädler, U., Schwarz, D. F., Wegener, A. A., Eichhorn, T., Bandeiras, T. M., Freitas, M. C., Lammens, A., Ganichkin, O. M., Augustin, M. A., Minguzzi, S., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105328 · Cited by 8

The HGF/MET Signaling and Therapeutics in Cancer

Thewke, D. P., Kou, J., Fulmer, M. L., & Xie, Q. R. (2017) · Current human cell research and applications · doi:10.1007/978-981-10-7296-3_8 · Cited by 8

Head and neck squamous cell carcinoma: Exploring frontiers of combinatorial approaches with tyrosine kinase inhibitors and immune checkpoint therapy

Scarini, J. F., Lavareze, L., de Lima‐Souza, R. A., Emerick, C., Gonçalves, M. T., Maciel, T. F., Vieira, G. D. S., Kimura, T. D. C., de Sá, R. S., Aquino, I. G., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103863 · Cited by 7

The Crosstalk of c-MET with Related Receptor Tyrosine Kinases in Urothelial Bladder Cancer

Lan, S., Wu, S., Raghavaraju, G., Chow, N., & Liu, H. (2013) · InTech eBooks · doi:10.5772/53718 · Cited by 7

Recepteur d'origine nantais (RON), more than a kinase: Role in castrate‐resistant prostate cancer

Batth, I. S., Yun, H., & Kumar, A. P. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22354 · Cited by 7

Promise and challenges on the horizon of MET-targeted cancer therapeutics

Zhang, Y.-W. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i2.16 · Cited by 7

Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma

Sfoungaristos, S., Giannitsas, K., & Perimenis, P. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.524928 · Cited by 6

Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase

Hudson, R., Yao, H., Suthe, S. R., Patel, D., & Wang, M. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666211222154129 · Cited by 6

Identification of Novel AXL Kinase Inhibitors Using Ligand-Based Pharmacophore Screening and Molecular Dynamics Simulations

Nagamalla, L., Kumar, J. V. S., Shaik, M. R., Chintakindi, S., Al-Samhan, A. M., Kasim, M. A., & Al‐Warthan, A. (2022) · Crystals · doi:10.3390/cryst12081158 · Cited by 6

Novel Pyrimido-Pyridazine Derivatives: Design, Synthesis, Anticancer Evaluation and In Silico Studies

Sonker, P., Singh, M., Nidhar, M., Sharma, V. P., Yadav, P., Singh, R., Koch, B., & Tewari, A. K. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0199 · Cited by 6

T6496 targeting EGFR mediated by T790M or C797S mutant: machine learning, virtual screening and bioactivity evaluation study

Wang, L., Fan, D., Ruan, W., Huang, X., Zhu, W., Tu, Y., & Zheng, P. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2300756 · Cited by 7

Systematic screen with kinases inhibitors reveals kinases play distinct roles in growth of osteoprogenitor cells.

Bao, N., Lü, M., Bin, F.-W., Chang, Z.-Y., Meng, J., Zhou, L., Guo, T., & Zhao, J.-N. (2013) · Europe PMC (PubMed Central) · Cited by 6

Molecular Basis of c-MET Inhibition by Approved Small Molecule Drugs: A Structural Perspective

Russell, I. C., Bachurska‐Szpala, P., van Beek, L., Michaelides, I. N., Phillips, C., Snijder, A., Stubbs, C. J., & Collie, G. W. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00713 · Cited by 5

Targeting breast cancer with rationally designed quinazolines: A scaffold hopping strategy

Lee, K., Nada, H., Gul, A. R., Elkamhawy, A., Elkamhawy, A., Park, T. J., Lee, K., & Choi, Y. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.138805 · Cited by 5

Structure-activity relationship study of 1,6-naphthyridinone derivatives as selective type II AXL inhibitors with potent antitumor efficacy

Zhuo, L., Guo, M., Zhang, S., Wu, J., Wang, M., Shen, Y., Peng, X., Wang, Z., Jiang, W., & Huang, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116090 · Cited by 5

Hypoxia, Metastasis, and Antiangiogenic Therapies

Siemann, D. W., Dai, Y., & Horsman, M. R. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9167-5_9 · Cited by 5

Determination of a novel anticancer c‐Met inhibitor LS‐177 in rat plasma and tissues with a validated UPLC‐MS/MS method: application to pharmacokinetics and tissue distribution study

Ju, P., Liu, Z., Jiang, Y., Zhao, S., Zhang, L., Zhang, Y., Gu, L., Tang, X., Bi, K., & Chen, X. (2014) · Biomedical Chromatography · doi:10.1002/bmc.3397 · Cited by 5

Kinase inhibitors: Opportunities for small molecule anticancer immunotherapies

Safaroghli‐Azar, A., Emadi, F., Lenjisa, J. L., Mekonnen, L. B., & Wang, S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103525 · Cited by 5

From Lab to Target: Pyrazole, Pyrazoline and Fused Pyrazole Derivatives as Receptor Tyrosine Kinase Inhibitors in Cancer Therapy

Sawiris, M. M., Khalil, O. M., Halim, P. A., & Hassan, M. S. A. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70061 · Cited by 5

Design, synthesis and biological evaluation of thienopyridine derivatives as c-Met kinase inhibitors

Xie, T., Hu, W., You, L., & Wang, X. (2024) · Molecular Diversity · doi:10.1007/s11030-024-10998-3 · Cited by 4

Expression and prognostic value of c‐met in canine mammary tumours

Chen, Y., Chen, Y., Liao, J., & Chang, S. (2018) · Veterinary and Comparative Oncology · doi:10.1111/vco.12439 · Cited by 4

Feed‐forward activation of STAT3 signaling limits the efficacy of c‐Met inhibitors in esophageal squamous cell carcinoma (ESCC) treatment

Zhao, D., Chen, J., Wang, Y., Zhang, L., Zhang, J., Zhang, W., Fan, J., Li, J., & Zhan, Q. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23306 · Cited by 4

ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs

Tsukamoto, S., Sugi, N. H., Nishibata, K., Nakazawa, Y., Ito, D., Fukushima, S., Nakagawa, T., Ichikawa, K., Kato, Y., Kakiuchi, D., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0879 · Cited by 5

Discovery of New Quinazoline Derivatives as VEGFR-2 Inhibitors: Design, Synthesis, and Anti-proliferative Studies

Dhawale, S. A., Dabhade, P. S., & Mokale, S. N. (2023) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520623666230714152455 · Cited by 4

Innovative molecular targeted agents in hepatocellular carcinoma: new gladiators on the arena

Ferri, J., Dockx, Y., Vonghia, L., Papadimitriou, K., Rasschaert, M. A., Francque, S., Peeters, M., & Rolfo, C. D. (2017) · Minerva Surgery · doi:10.23736/s0026-4733.17.07311-4 · Cited by 4

Dysbiotic stress increases the sensitivity of the tumor vasculature to radiotherapy and c-Met inhibitors

Jenkins, S. V., Alimohammadi, M., Terry, A. S., Griffin, R. J., Tackett, A. J., Leung, J. W. C., Vang, K. B., Byrum, S. D., & Dings, R. P. M. (2021) · Angiogenesis · doi:10.1007/s10456-021-09771-z · Cited by 5

Identification of a 7H-pyrrolo[2,3-d]pyrimidin derivatives as selective type II c-Met/Axl inhibitors with potent antitumor efficacy

Qin, S., Xie, L., Tang, M., Ni, H., & Yang, T. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108187 · Cited by 3

PROTACs improve selectivity for targeted proteins

Liu, L., Guan, X., Zhuo, J., Wu, X., & Han, X. (2025) · Acta Materia Medica · doi:10.15212/amm-2025-0015 · Cited by 3

Scaffold-hopping strategy for pyrazolo[3,4-d]pyrimidines: In vitro and in silico studies of dual c-Met/STAT3 inhibition for enhanced antitumor activity

El-Desouky, S. I., Nafie, M. S., Haffez, H., Moustafa, M. A. A., & Ali, A. R. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108821 · Cited by 4

Synthesis, Characterization, Biological and Molecular Docking Studies of 1,3-Diphenyl-1H-pyrazole Terminated Imino Derivatives

Sandhya, P. V., Niyas, K. V. M., & Haridas, K. R. (2021) · Asian Journal of Chemistry · doi:10.14233/ajchem.2021.23220 · Cited by 3

Homology Modelling, Docking-based Virtual Screening, ADME Properties, and Molecular Dynamics Simulation for Identification of Probable Type II Inhibitors of AXL Kinase

Bhojwani, H. R., & Joshi, U. J. (2021) · Letters in Drug Design & Discovery · doi:10.2174/1570180818666211004102043 · Cited by 4

Targeting Molecular Aberrations in Urothelial Carcinoma: Are We Almost There?

Apolo, A. B., & Kwiatkowski, D. J. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.195 · Cited by 3

Supported Transition Metal Catalysts for Organic Fine Chemical Synthesis: A Review

Mistri, R., & Kumar, B. (2021) · Asian Journal of Chemistry · doi:10.14233/ajchem.2021.23025 · Cited by 3

Advances in the Scientific Evaluation of Bladder Cancer and Molecular Basis for Diagnosis and Treatment

Persad, R. A., & Ranasinghe, W. (2013) · InTech eBooks · doi:10.5772/56665 · Cited by 3

Synthesis of Novel Indole-Benzimidazole Derivatives

Wang, X., Liu, Y., Xu, J., Jiang, F., & Kang, C. (2016) · Journal of Chemical Research · doi:10.3184/174751916x14737735069962 · Cited by 3

Therapeutic Considerations for Ron Receptor Expression in Prostate Cancer.

Brown, N. E., Sullivan, C., & Waltz, S. E. (2018) · PubMed · Cited by 3

In Silico Analysis of Triamterene as a Potential Dual Inhibitor of VEGFR-2 and c-Met Receptors

Lutimba, S., Saleem, B., Aleem, E. A., & Mansour, M. A. (2024) · Journal of Xenobiotics · doi:10.3390/jox14040105 · Cited by 2

Design, Synthesis, and In Silico Insights of new 4‐Piperazinylquinolines as Antiproliferative Agents against NCI Renal Cancer Cell Lines

Monica, G. L., Bono, A., Alamia, F., Martorana, A., & Lauria, A. (2025) · ChemistryOpen · doi:10.1002/open.202400518 · Cited by 2

Fexofenadine Overcomes Osimertinib Resistance by Inhibiting c‐Met in Non‐Small Cell Lung Cancer

To, K. K. W., Leung, K., & Cho, W. C. S. (2025) · MedComm – Oncology · doi:10.1002/mog2.70019 · Cited by 2

C-MET tyrosine kinase receptor: mechanisms, clinical applications and future perspectives in cancer therapy

Zhu, C., Li, Y., Xu, H., Sun, L., Wei, Y., 马承娴, Chen, Q., & He, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02682-9 · Cited by 4

Identification of potentially high drug-like VEGFR2/c-Met dual-target type II kinase inhibitors with symmetric skeletons based on structural screening

Xie, J., Zhang, X., Meng, D., Li, Y., & Deng, P. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2199082 · Cited by 2

Discovery of Novel Pyrimidine Based Small Molecule Inhibitors as VEGFR-2 Inhibitors: Design, Synthesis, and Anti-cancer Studies

Dhawale, S. A., Mokale, S. N., & Dabhade, P. S. (2024) · Current Computer - Aided Drug Design · doi:10.2174/0115734099269413231018065351 · Cited by 2

Studying the Binding Modes of Novel 2-Aminopyridine Derivatives as Effective and Selective c-Met Kinase Type 1 Inhibitors Using Molecular Modeling Approaches

Ye, Q., Fu, C., & Li, J. (2020) · Molecules · doi:10.3390/molecules26010052 · Cited by 2

RECENT ADVANCES IN DRUGS TARGETING PROTEIN KINASES FOR CANCER THERAPY.

Mahdy, H. A., Shaat, M., & Ayyad, R. R. A. (2022) · Al-Azhar Journal of Pharmaceutical Sciences/Al-Azhar Journal of Pharmaceutical Sciences · doi:10.21608/ajps.2022.268384 · Cited by 2

Design, synthesis and biological evaluation of sulfonylamidines as potent c-Met inhibitors by enhancing hydrophobic interaction

Nan, X., Li, X., Wu, Y., Li, H., Wang, Q., Xing, S., & Liang, Z. (2023) · Organic & Biomolecular Chemistry · doi:10.1039/d3ob01156a · Cited by 2

Novel Targeted Agents in Head and Neck Squamous Cell Carcinoma

Velho, P. H. I., de Castro, G., & Chung, C. H. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.07.006 · Cited by 2

Abstract 3613: Dual inhibitors against receptor tyrosine kinases c-Met and VEGFR-2 as efficacious antitumor agents in mouse xenograft tumor models

Wang, Q., Lu, W., Xing, X., Chen, M., Liu, Y., Zhao, L., Li, W., & Jiang, S. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-3613

A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities

Awazu, Y., Nakamura, K., Mizutani, A., Kakoi, Y., Iwata, H., Yamasaki, S., Miyamoto, N., Imamura, S., Miki, H., & Hori, A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1011 · Cited by 28

Inhibition of tumor cell growth, invasion, and metastasis by SIM-89, a novel inhibitor of HGF receptor tyrosine kinases.

Pei, J., Han, B., Shao, M., & Sha, H. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.e13528

Discovery and characterization of INCB028060, a novel, potent and selective Met RTK inhibitor for cancer treatment

Liu, X., Koblish, H. K., Wang, Q., Yang, G., Hall, L. M., Wen, X., Marando, C. A., Behshad, E., Wynn, R., Becker-Pasha, M., et al. (2008) · Cancer Research · Cited by 4

VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer

You, W., Sennino, B., Williamson, C. W., Falcón, B. L., Hashizume, H., Yao, L., Aftab, D. T., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2527 · Cited by 262